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Introduction: Autoantibodies contribute significantly to the pathogenesis of systemic lupus erythematosus (SLE).
Unfortunately, the long-lived plasma cells (LLPCs) secreting such autoantibodies are refractory to conventional
immunosuppressive treatments. Although generated long before the disease becomes clinically apparent, it remains
rather unclear whether LLPC generation continues in the established disease. Here, we analyzed the generation of
LLPCs, including autoreactive LLPCs, in SLE-prone New Zealand Black/New Zealand White F1 (NZB/W F1) mice over
their lifetime, and their regeneration after depletion.
Methods: Bromodeoxyuridine pulse-chase experiments in mice of different ages were performed in order to analyze the
generation of LLPCs during the development of SLE. LLPCs were enumerated by flow cytometry and autoreactive
anti-double-stranded DNA (anti-dsDNA) plasma cells by enzyme-linked immunospot (ELISPOT). For analyzing the
regeneration of LLPCs after depletion, mice were treated with bortezomib alone or in combination with cyclophosphamide
and plasma cells were enumerated 12 hours, 3, 7, 11 and 15 days after the end of the bortezomib cycle.
Results: Autoreactive LLPCs are established in the spleen and bone marrow of SLE-prone mice very early in ontogeny,
before week 4 and before the onset of symptoms. The generation of LLPCs then continues throughout life. LLPC
counts in the spleen plateau by week 10, but continue to increase in the bone marrow and inflamed kidney. When
LLPCs are depleted by the proteasome inhibitor bortezomib, their numbers regenerate within two weeks. Persistent
depletion of LLPCs was achieved only by combining a cycle of bortezomib with maintenance therapy, for example
cyclophosphamide, depleting the precursors of LLPCs or preventing their differentiation into LLPCs.
Conclusions: In SLE-prone NZB/W F1 mice, autoreactive LLPCs are generated throughout life. Their sustained
therapeutic elimination requires both the depletion of LLPCs and the inhibition of their regeneration.* Correspondence: bimba.hoyer@charite.de
ˆDeceased
1Department of Rheumatology and Clinical Immunology, Charité University
Hospital Berlin, Charitéplatz 1, 10117 Berlin, Germany
2German Rheumatism Research Centre, a Leibniz Institute, Charitéplatz 1,
10117 Berlin, Germany
Full list of author information is available at the end of the article
© 2015 Taddeo et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Taddeo et al. Arthritis Research & Therapy  (2015) 17:39 Page 2 of 12Introduction
Systemic lupus erythematosus (SLE), the prototype of a
systemic autoimmune disease, is characterized by the pro-
duction of pathogenic autoantibodies that directly or indir-
ectly contribute to the pathogenesis of SLE, resulting in
cell destruction and inflammation [1,2]. NZB/W mice
spontaneously develop a disease closely resembling human
SLE. We have shown before that these mice develop both
long-lived and short-lived autoreactive plasma cells, and
that long-lived plasma cells (LLPCs) contribute signifi-
cantly to the production of pathogenic autoantibodies [3].
These LLPCs are able to induce nephritis when transferred
into immunodeficient mice [4]. As they are refractory to
immunosuppressive drugs (for example, cyclophospha-
mide, dexamethasone and a combination of the two) and
B cell depletion, they represent a therapeutic challenge in
the treatment of SLE [3,5,6].
Autoantibodies are detectable years before the clinical
onset of SLE in humans [7], and by the age of only
4 weeks in NZB/W mice ([3,8] and unpublished data).
Some of these autoantibodies are produced by LLPCs
since they do not disappear upon treatment of humans
or mice with drugs like cyclophosphamide [3,9] or ritux-
imab [10,11]. However, it remains controversial when
this population of refractory LLPCs is established in the
course of the disease. We have previously shown that a
population of autoreactive LLPCs exists in the spleen
and bone marrow by week 24 of life [3]. Whether such
population is established early in disease pathogenesis
and no longer formed later, when constant generation of
short-lived plasma cells (SLPCs) may become a hallmark
of pathology [12], remain unclear. Alternatively, it has
been proposed that a constant generation and turnover
of the LLPC pool may be sustained by B cell hyperreac-
tivity [13,14], but also this hypothesis remains to be elu-
cidated. This is valuable information in order not to
miss an ‘LLPC window of opportunity’ at the beginning
of the disease. Moreover, although interesting studies
showed that B cells are able to repopulate the plasma
cell-deficient bone marrow [15], it remains rather un-
clear whether in autoimmunity LLPCs may be replen-
ished from autoreactive memory B cells after therapeutic
depletion of these cells.
Here, we show that LLPC generation starts very early
in NZB/W F1 mice, long before clinical onset of disease.
Then, LLPC counts in the spleen plateau after about
10 weeks, but those in the bone marrow and inflamed
kidney increase over lifetime. When PCs are eliminated
by bortezomib [16], LLPC counts recover within 15 days
in both the spleen and bone marrow. Thus, for persist-
ent elimination of autoreactive LLPCs, existing LLPCs
must be depleted (for example, by a cycle of bortezo-
mib), and their regeneration must be prevented by main-
tenance therapy. Maintenance therapy could be directedat eliminating precursor cells or preventing their activa-
tion. Here, we used a combination of bortezomib with
cyclophosphamide as a model to demonstrate that, in con-
trast to bortezomib or cyclophosphamide alone, this com-
bination therapy achieves sustained elimination of LLPCs.
Methods
Mice
Female NZB/W F1 mice were bred and maintained under
specific pathogen-free (SPF) conditions at the mouse facil-
ity of German Rheumatism Research Centre, Berlin. All
experiments were performed according to German guide-
lines for the performance of animal experiments and
approved by the according authority (Landesamt für
Gesundheit und Soziales, Berlin).
Flow cytometry and ELISPOT
Flow cytometric analysis of spleen and bone marrow cells
was performed after two weeks of bromodeoxyuridine
(BrdU) feeding (see below). Staining was performed as de-
scribed previously [3]. The following antibodies were used
for the analysis: anti-CD138 (2-218, BD Pharmingen, San
Diego, CA, USA), anti-MHCII (clone M5/114, DRFZ,
Berlin, Germany) and anti-kappa light chain (clone 187.1,
BD Pharmingen). Cells were acquired using a FACS BD
LSR II or FACSCanto II or LSRFortessa flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed
using FlowJo software (TreeStar, San Carlos, CA, USA).
Debris and red blood cells (RBCs) were excluded by elec-
tronic gating. As the ratio of kappa- to lambda-producing
plasma cells is 20:1 in mice, we used single intracellular
staining with anti-kappa light chain to determine the num-
ber of plasma cells. Plasma cells were identified as CD138+
and intracellular anti-kappa light chain-positive cells. The
staining was initially validated using fluorescence-minus-
one (FMO) controls for the two markers. This population
presents a clear bimodal expression of the markers, with
no overlap of positive and negative populations, not requir-
ing any further control for determination of positive and
negative populations [17]. Within the plasma cells popula-
tion, plasmablasts and newly generated plasma cells were
identified as cells with the higher expression of MHC-II.
Conversely MHC-IIlow plasma cells were regarded as
LLPCs. The expression of MHC-II on B220-positive
cells was used to determine the cutoff between high (same
MHC-II expression of B220+ cells) and low (lower MHC-II
expression as compared to B220+ cells) MHC-II-expressing
plasma cells. BrdU staining was performed with anti-BrdU
antibody using the BD Pharmingen BrdU FlowKit™ accord-
ing to the manufacturer’s recommendations.
Enzyme-linked immunospot (ELISPOT) analysis to deter-
mine the absolute numbers of anti-double-stranded DNA
(anti-dsDNA)-specific antibody-secreting cells (ASCs) was
performed as described previously [3,18]. Briefly, ELISPOT
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Darmstadt, Germany) were pre-coated with methyl-BSA
(10 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 2 h at
37°C and subsequently coated with calf thymus DNA
(10 μg/ml; Sigma-Aldrich) overnight. Spleen, bone marrow
and kidney single-cell suspensions were filtered twice
through a Falcon cell strainer (70 μm), washed and resus-
pended in RPMI 1640 medium supplemented with 10%
fetal calf serum (FCS). After plate blocking, two different
cell dilutions were pipetted onto the plates and incubated
for 3 h at 37°C in a humid atmosphere with 5% CO2.
After extensive washing, plates were incubated with
biotin-labeled goat anti-mouse immunoglobulin G
(IgG) and immunoglobulin M (IgM) (1 μg/ml, Southern
Biotech, Birmingham, AL, USA) for 1 h and followed
by ExtrAvidin™-alkaline phosphatase (Sigma-Aldrich) for
20 min. The spots were developed with NBT/BCIP
(Thermo Fisher Scientific, Waltham, MA, USA) and enu-
merated using an automated ELISPOT reader and soft-
ware (AID Diagnostika, Strassberg, Germany).
Cell count
Absolute cell numbers of spleen, bone marrow and kid-
neys were assessed by automatic cell counting either by
Schaerfe CASY Cell Counter (Schaerfe System GmbH,
Reutlingen, Germany) or by MACSQuant Analyzer
(Miltenyi Biotec, Cologne, Germany). Absolute plasma cell
numbers were calculated based on total cell numbers (by
automatic cell counting) and frequencies of cell types in
each organ measured by flow cytometry. For ELISPOT
assay, the absolute numbers of ASCs per organ were cal-
culated by the number of spots/well multiplied by the di-
lution factor of the cell suspension used for the assay. The
total number of bone marrow cells was calculated based
on the assumption that both femoral bones contain ap-
proximately 8% of total bone marrow cells [16].
LLPC generation
BrdU pulse-chase experiments
In the experiments analysing the generation of LLPC
over the lifetime mice of different ages (4 to 32 weeks)
were given BrdU in their drinking water (protected from
light, 1 mg/ml + 1% glucose) for two weeks in order to
determine the time point of formation of the LLPC com-
partment. This made it possible to discriminate between
cells generated during and before the feeding period. As
shown previously, this two-week feeding interval is suffi-
cient for discriminating between short- and long-lived
plasma cells [3].
In the experiments dissecting the capacity to generate
LLPC at different age, mice were continuously fed BrdU
for six weeks from the ages of 4 to 10 weeks (young)
and 20 to 26 weeks (old). Six weeks after the end of the
feeding period, the number of surviving BrdU-positiveplasma cells was measured. These cells are LLPCs that
were generated during the feeding period and survived
the next six weeks.
Autoreactive LLPCs formation
To characterize the establishment kinetics of autoreactive
(anti-dsDNA) LLPCs, plasmablasts and SLPCs were de-
pleted in NZB/W F1 mice at different ages (4, 6, 8 and 20,
24, 30 weeks of age) by administering four injections of
cyclophosphamide (35 mg/kg bw) within two weeks [3].
After treatment, the remaining anti-dsDNA-specific LLPCs
were enumerated in spleen and bone marrow by ELISPOT.
Plasma cell depletion
Twelve- to 16-week-old NZB/W F1 mice with an estab-
lished plasma cell pool received a single bortezomib cycle
consisting of two intravenous (i.v.) injections (0.75 mg/kg
bw) of bortezomib over a 36-hour interval. For the com-
bination treatment, mice were additionally treated with
35 mg/kg bw cyclophosphamide alone or in combination
with the starting of the bortezomib cycle. Cyclophospha-
mide was re-administered every four days until the end of
the experiment. Twelve hours and 3, 7 and 15 days after
the last bortezomib injection, the mice were sacrificed and
their spleen and bone marrow cells were characterized
and quantified by flow cytometry and ELISPOT. MHC-II
expression on the plasma cells population was analyzed to
discriminate between plasmablasts and newly generated
plasma cells (MHC-IIhigh) and mature LLPCs (MHC-IIlow)
in these experiments [3]. As previously shown, expression
of MHC-II correlates well with the expansion phase of the
plasma cell population and can be used as a surrogate
marker to distinguish proliferating plasmablasts from non-
cycling plasma cells [3,19]. This is in accordance with the
observation that all BrdU-negative LLPCs expressed little
MHC-II and BrdU-positive SLPCs expressed high levels of
this molecule, with the limitation that in the BrdU-
positive population of SLPCs also some MHC-II low cells
are included, which may be newly generated LLPCs.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA, USA). If not
otherwise indicated, the indicated numbers are means
with standard error of the mean (SEM). Statistical signifi-
cance was calculated using the unpaired two-tailed Stu-
dent t test. P values <0.05 were regarded as significant.
Results
LLPC generation in SLE-prone mice
The generation of LLPCs in NZB/W F1 mice starts early in
ontogeny and continues through life
To analyze the generation of LLPCs in SLE-prone NZB/
W F1 mice over their lifetime, young (age: 4, 6, 8, and
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ceived BrdU (1 mg/ml) in their drinking water for two
weeks. BrdU-negative CD138+ plasma cells (those which
had not performed DNA synthesis during the two weeks
of BrdU feeding) were classified as long-lived [3].
In six-week-old mice, 17% (±3%) of all plasma cells in
the spleen were LLPCs, which were initially generated
before the age of 4 weeks (Figure 1A), long before the
clinical onset of disease. The frequency of LLPCs in-
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Figure 1 The majority of long-lived plasma cells (LLPCs) are generate
frequencies of bromodeoxyuridine (BrdU)-negative LLPCs of total CD138+
organ. Mice of 4, 6, 8, 12 and 24, 26, 27 weeks of age were fed BrdU contin
analysis of splenic and bone marrow plasma cells. n = 4 mice per time poin
LLPC and BrdU-positive short-lived plasma cells (SLPC) measured by flow c
secreting cells (ASCs) measured by enzyme-linked immunospot (ELISPOT) (
26 and 30 weeks of age were fed BrdU continuously for two weeks and th
ELISPOT of kidney plasma cells. n = 4-11 mice per time point. Data are pres
horizontal bars represent P values from statistical comparison between timand remained without significant changes until the end of
the observation period (29 weeks of age). At that time, all
of the mice had full-blown disease. In terms of absolute
cell counts, the numbers of splenic LLPCs increased by
250,000 cells on average between weeks 6 to 8, by another
207,000 by week 10, and by a further 60,000 by week 14
(Figure 1B). Then the number of LLPCs in the spleen did
not change significantly between week 14 and week 29. In
the bone marrow, the LLPC frequency increased from
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age, LLPC frequencies increased to 45 to 50% of all plasma
cells. The absolute numbers of bone marrow LLPCs in-
creased on average by 22,000 cells between weeks 6 to 8,
by another 62,000 cells between weeks 8 to 10, and by
92,000 between weeks 10 to 14 (Figure 1B). Thereafter, the
numbers of LLPCs increased further by on average 128,000
between weeks 14 and 24 and by 1,082,000 between weeks
26 to 29. Therefore, LLPC generation starts very early in
ontogeny, that is, before the onset of symptoms.
Plasma cells may also accumulate in the kidney of NZB/
W F1 mice with full-blown disease [14,18,20]. To analyze
the kinetic of accumulation of LLPCs in the kidney, mice
of 6, 14, 20, 26 and 30 weeks of age were fed BrdU con-
tinuously for two weeks and then subjected to BrdU in-
corporation analysis and the absolute numbers of total
plasma cells, BrdU-negative LLPCs and BrdU-positive
SLPCs were measured by flow cytometry. Plasma cells ap-
pear in the kidney from week 16 of age, and then accumu-
late without reaching a plateau (Figure 1C). The number
of LLPCs increased on average from 51 cells at 16 weeks
of age to 13,181 cells at 32 weeks of age in the two kid-
neys. The number of SLPCs increased on average from 56
cells at 16 weeks of age to 10,900 cells at 32 weeks of age.
Accordingly, the number of autoreactive plasma cells se-
creting antibodies against ds-DNA (IgG and IgM isotypes)
measured by ELISPOT, constantly increased in the kidney
from week 16, peaking at the end of the observation
period (32 weeks of age) without reaching a plateau.
Therefore, the generation of LLPCs continues throughout
life and, at later stage of disease, LLPCs persistently accumu-
late in the bone marrow and kidney but not in the spleen.
The generation of LLPCs continues with age and disease
progression
In order to understand whether the capacity to form LLPCs


















































Figure 2 Generation of long-lived plasma cells (LLPCs) continues with
number (right) of bromodeoxyuridine (BrdU)-positive newly generated LLP
mice. Young (4 weeks of age) and old (20 weeks of age) NZB/W F1 mice w
performed six weeks after the end of BrdU feeding. Cells were gated on CD
during the BrdU feeding period. Data are presented as mean and standard
represent P values from statistical comparison between groups by two-taileW F1 mice (without signs of disease activity and very low
levels of dsDNA-antibodies) and 20-week-old NZB/W F1
mice (with mild disease, low proteinuria, and high autoanti-
body titers) were fed BrdU for six weeks (from weeks 4 to
10 or from weeks 20 to 26 of age, respectively). BrdU feed-
ing was then stopped and animals were kept for another six
weeks without further BrdU feeding. The spleen and bone
marrow of the mice were then analyzed for persistent,
BrdU-labeled cells. These BrdU-positive cells, which must
have been generated during the preceding BrdU feeding
period, can thus be regarded as LLPCs that were generated
in the feeding period. Twenty-one ± 3% (83,487 ± 3,018
cells/organ) and 14 ± 2% (28,300 ± 1,821 cells/organ) of
the plasma cells in spleen and bone marrow of 16-week-
old mice, respectively, were LLPCs that had been ge-
nerated between weeks 4 and 10 of age (Figure 2). In
32-week-old mice, 4.3 ± 0.9% (14,302 ± 2,756 cells/organ)
of splenic plasma cells and 13 ± 1.7% (52,362 ± 4,028 cells/
organ) of bone marrow plasma cells were LLPCs generated
between weeks 20 to 26 of age (Figure 2). Thus, LLPCs ac-
cumulate in the spleen mostly early in life (until week 10),
but accumulate in the bone marrow throughout life, at
constant rates.
Generation of autoreactive LLPCs
To understand whether the generation of autoreactive
LLPCs followed the same kinetics as compared to total
LLPCs, SLPCs were eliminated from the analysis by inject-
ing four doses of cyclophosphamide in the two weeks
prior to the analysis [3]; the remaining dsDNA-specific
LLPCs in the spleen and bone marrow were enumerated
by ELISPOT. In the spleen, IgM dsDNA-specific LLPCs
increased 1.8-fold between weeks 6 to 10 of age and then
reached a plateau (0.7 fold change) between weeks 10 to
32 (Figure 3). Splenic IgG dsDNA-specific LLPCs in-
creased 2.6-fold between weeks 6 to 10 of age, plateaued
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Figure 3 Autoreactive long-lived plasma cells (LLPCs) are early and continuously generated in NZB/W mice. Absolute numbers of
cyclophosphamide-resistant LLPCs secreting double-stranded DNA (dsDNA)-specific antibody in spleen and bone marrow. NZB/W F1 mice at 4, 6,
8 and 20, 24, 30 weeks of age were treated with four injections of cyclophosphamide (35 mg/kg bw) within two weeks in order to deplete plasmablasts
and short-lived plasma cells [3]. After treatment, the remaining anti-dsDNA-specific LLPCs were enumerated by enzyme-linked immunospot (ELISPOT).
Data are presented as mean and standard error of the mean (SEM). n = 4-5 mice per time point.
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dsDNA-specific LLPCs increased 3.8-fold between weeks
6 to 10, and further increased at constant rates until week
26. IgG dsDNA-specific LLPCs in the bone marrow
showed this same steep increase, but delayed. Between 6
to 10 weeks of age, the numbers remained stable, but in-
creased 4-fold at constant rates from 10 to 26 weeks of
age (Figure 3).
This demonstrates that the generation of autoreactive
LLPCs starts early in life and that autoreactive LLPCs
continue to accumulate at constant rates in the bone
marrow of NZB/W mice throughout life.
Depletion and regeneration of LLPCs
LLPCs of NZB/W F1 mice were depleted by a single bor-
tezomib cycle consisting of two injections of bortezomib
(0.75 mg/kg bw; 36-hour interval) [16]. Twelve hours after
the last injection, plasma cell counts had decreased on
average from 741,949 to 410,617 in the spleen (72 ± 42.4%
decrease) (P = 0.0161) and from 881,886 to 332,620 in the
bone marrow (74.1 ± 30% decrease) (P = 0.0014) (Figure 4A
and B), but recovered later. On day 15 after bortezomib
treatment, splenic and bone marrow counts had reached
140% and 70% of the number in untreated mice (day 0),
respectively (Figure 4B). On average about 50% and 68%
of newly generated plasma cells (day 15) in the spleen and
bone marrow, respectively, were LLPCs according to ex-
pression of MHC class II (Figure 4A). Twelve hours after
the last bortezomib injection, autoreactive dsDNA-specific
plasma cells (enumerated here as ASCs either secreting
IgG- or IgM-dsDNA antibodies) in spleen and bone mar-
row were depleted up to 50% of the number in untreated
mice. However, 15 days later, they regenerated, reaching a
higher number as compared to untreated mice in both the
spleen and bone marrow (Figure 4C). Interestingly, the de-
pletion of anti-dsDNA plasma cells was not as efficient as
the depletion of total plasma cells. The ELISPOT assay inthis experiment was designed for the enumeration of all
the ASCs producing either IgM- or IgG-dsDNA antibodies.
Further experiments showed that ASCs producing IgM-
dsDNA are particularly resistant to bortezomib-mediated
depletion (with only 40 to 50% reduction) whereas IgG-
dsDNA ASCs are efficiently depleted (70 to 80% reduction)
(manuscript in preparation).
Persistent depletion of autoreactive LLPCs
Twelve- to 16-week-old NZB/W F1 mice were treated
with a cycle of bortezomib, cyclophosphamide alone or
with a combination of the two. Cyclophosphamide was
injected intraperitoneally (i .p.) on day 0, 3, 7 and 11 after
the bortezomib cycle in order to deplete plasma cells and,
on the other hand, to block their regeneration (Figure 5).
We have previously shown that cylophosphamide can
eliminate SLPCs from the spleen but that LLPCs in spleen
and bone marrow (including anti-dsDNA ASCs) survive
the treatment [3,5]. Plasma cell numbers in the spleen and
bone marrow were determined 12 hours and 3, 7 and
15 days after the last bortezomib treatment. Confirming
our previous results [3,5], the treatment with four doses of
cyclophosphamide alone induced a significant reduction of
SLPC numbers and only a slight decrease of splenic
LLPC numbers without affecting LLPCs in bone marrow
(Figure 5A). The combination of a cycle of bortezomib
with cyclophosphamide induced a further tendential reduc-
tion of splenic LLPC numbers at the end of the observation
period (from an average of 248,667 in cyclophosphamide-
treated mice to 111,708 in mice treated with the combin-
ation therapy). Importantly, at the end of the observation
period (15 days after bortezomib treatment) in the bone
marrow, the combination of bortezomib with cyclophos-
phamide maintained the LLPC numbers significantly lower
as compared to the groups treated with the single therapy
(on average 98,844 LLPCs in the bone marrow of mice
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Figure 4 (See legend on next page.)
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Figure 4 Bortezomib-mediated long-lived plasma cell (LLPC) depletion is transient. Twelve- to 16-wk-old NZB/W F1 mice were treated with
one bortezomib cycle consisting of two bortezomib injections within 36 h and analyzed 12 h and 3, 7 and 15 days after the last bortezomib injection.
(A) Representative gating strategy for plasma cell analysis by flow cytometry. Lymphocytes were gated according to their position in forward and
sideward scatter, and doublets were excluded from the analysis (not shown). Plasma cells were identified as CD138+ and intracellular kappa light
chain + cells both in spleen and bone marrow. Within the plasma cells population, plasmablasts and newly generated plasma cells were identified as
cells with a higher expression of MHC-II. Conversely, MHC-IIlow plasma cells were regarded as LLPCs. A representative plot of the expression of MHC-II
on the plasma cell population is shown for spleen and bone marrow 15 days after bortezomib treatment. (B) Absolute numbers of all CD138+/intracellular
kappa light chain + plasma cells (white bars) and the subgroups of short-lived, MHChigh (gray bars) and long-lived, MHC-IIlow (black bars) plasma cells in
spleens (left) and bone marrows (right) 12 h (0.5 days), 3, 7 and 15 days after one cycle of bortezomib measured by flow cytometry. n = 7 mice per time
point. (C) Frequencies of the remaining anti-double-stranded DNA (dsDNA) antibody-secreting cells (ASCs) (immunoglobulin G (IgG) and immunoglobulin
M (IgM) combined) in spleen (left) and bone marrow (right) calculated by comparison with untreated mice (day 0), as detected by enzyme-linked
immunospot (ELISPOT). n = 4 mice per time point. Data are presented as mean and standard error of the mean (SEM). n.s., nonsignificant. P >0.05,
*P ≤0.05, **P ≤0.01 by two-tailed unpaired t test.
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cyclophosphamide or bortezomib therapy, respectively)
(Figure 5A). Accordingly, 15 days after the last bortezomib
injection, plasma cells secreting autoantibodies binding to
dsDNA (enumerated here as ASCs either secreting IgG or
IgM-dsDNA antibodies) were depleted to 19 ± 6% in
spleen by bortezomib and cyclophosphamide and only to
56 ± 37% in mice treated only with cyclophosphamide
(Figure 5B). In bone marrow, anti-dsDNA plasma cells
were depleted to 24 ± 0.5% and only to 80 ± 5% in mice
treated only with cyclophosphamide (Figure 5B). Thus,
combination treatment consisting of a single cycle of bor-
tezomib to deplete plasma cells together with continued
suppression of LLPC regeneration by cyclophosphamide
results in persistent ablation of autoreactive plasma cells.
Discussion
Here, we showed for the first time that the generation of
autoreactive LLPCs in SLE-prone NZB/W mice starts very
early in life, long before the onset of disease. Already mice
at the age of 4 weeks had anti-dsDNA-secreting plasma
cells resistant to cyclophosphamide in both bone marrow
and spleen. In the bone marrow, autoreactive LLPC
counts increased at a stable rate over life without reaching
a plateau, even in six-month-old mice. In the spleen, LLPC
numbers increased only in the first 12 weeks and then
remained stable over time. This demonstrates that auto-
reactive LLPCs are constantly generated in NZB/W mice
and that, later in life, they accumulate in the bone marrow
and inflamed kidney but not in the spleen. These findings
pose a therapeutic challenge since LLPCs are resistant to
conventional immunosuppression (for example, high-dose
cyclophosphamide and/or dexamethasone) or B cell-
depletion strategies [3,5,6]. They can be efficiently ablated
by proteasome inhibition with bortezomib [16]. However,
after depletion of LLPCs with bortezomib, the LLPC
counts recovered within 15 days reaching the levels of un-
treated mice. Thus, for maintained ablation of autoreactive
plasma cells, the regeneration of LLPCs must be blocked
as well. Here, we showed that depletion of plasma cells bybortezomib in combination with a maintenance therapy to
prevent the regeneration of autoreactive LLPCs results in
persistent ablation of autoreactive LLPC in NZB/W mice.
Are these findings of any relevance for human auto-
immune diseases?
SLE autoantibodies are considered to be pathogenic in
human SLE [1], and some of them can be produced by
LLPCs especially in refractory patients, as determined
based on their resistance to cyclophosphamide and B
cell-depleting therapy as with rituximab [6,9]. Moreover,
their titers increase over time in active disease [1], indi-
cating continued generation of autoreactive LLPCs. Re-
markably, plasma cell generation has been identified as a
marker of active disease [21-23]. Furthermore, elimin-
ation of all plasma cells including LLPC and B cells (that
is, their precursors) by anti-thymocyte globulin (ATG)
followed by autologous stem cells transplantation leads
to long-term remission in SLE patients [9]. All of this
evidence strongly suggests that the continuous gener-
ation of autoreactive LLPCs, their important role in dis-
ease pathogenesis and the need of targeting B cells and
plasma cells for the therapeutic elimination of the auto-
reactive LLPCs, are modeled by NZB/W mice.
Notably, the dynamics of generation and maintenance
of autoreactive LLPCs is not only determined by the rate
of generation, but also by the capacity of the body to
support LLPCs in the long run. It has been shown that
the number of plasma cells in human and mouse bone
marrow is determined by the number of chemokine (C-
X-C motif ) ligand 12 (CXCL12)-expressing stromal cells,
which organize survival niches for individual LLPCs
[24]. The frequency of such stromal cells in the bone
marrow is approximately 1%; accordingly, the physio-
logical frequency of bone marrow plasma cells is also
about 1% [25]. Thus, about 109 and 106 LLPCs can be
hosted in the bone marrow of healthy humans or
healthy mice, respectively [12,25]. Here we found that
the maximum capacity to support LLPC survival in the
spleen is reached after only 12 weeks, in line with our
previous findings [3]. In the bone marrow, this number









































































































Figure 5 Persistent depletion of long-lived plasma cells (LLPCs) using cyclophosphamide in combination with bortezomib. Twelve- to
16-wk-old NZB/W F1 mice were treated with: (1) one bortezomib cycle (black dots and black line); (2) intraperitoneal injection of 35 mg/kg bw
cyclophosphamide on day 0, 3, 7 and (open dots, dotted line); (3) one bortezomib cycle combined with cyclophosphamide on day 0, 3, 7 and 11
(gray dots, connecting line). (A) Absolute numbers of short-lived MHChigh in the spleen and long-lived MHC-IIlow plasma cells in the spleen (left)
and bone marrow (right) 12 h and 3, 7, and 15 days after the last bortezomib injection measured by flow cytometry. (B) Frequencies of the
remaining anti-double-stranded DNA (anti-dsDNA)-secreting cells in the spleen (left) and bone marrow (right) calculated by comparison with
untreated mice (day 0), as detected by enzyme-linked immunospot (ELISPOT) 15 days after the last bortezomib injection. n = 4 mice treated with
bortezomib, n = 3 with cyclophosphamide and n = 4 with bortezomib plus cyclophosphamide. Data represent mean and standard error of the
mean (SEM). Numbers and horizontal bars represent P values from statistical comparison between groups at the end of the observation period
(15 days after the bortezomib cycle). n.s., nonsignificant. P >0.05, *P ≤0.05, **P ≤0.01 by two-tailed unpaired t test.
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period). Importantly, LLPCs accumulate in the inflamed
kidney of SLE mice at a later stage of the disease, confirm-
ing that nephritic kidneys can provide survival niches for
LLPCs [14,18,20], increasing the capacity to support LLPC
survival during disease. In humans, the situation may be
slightly different in that a patient’s capacity to host LLPCs
in the bone marrow may be reached before disease onsetor early in disease. Nevertheless, the new LLPCs can be
generated and maintained efficiently, likely by newly
formed plasmablasts outcompeting LLPC for their survival
niches [12,26] or, most probably, by homing of new auto-
reactive LLPCs in new niches in inflamed tissues as shown
by us and others for SLE mice [14,18,20].
Our findings have relevant clinical implications. As
discussed above, the existence of autoreactive LLPCs is a
Taddeo et al. Arthritis Research & Therapy  (2015) 17:39 Page 10 of 12therapeutic challenge. Considering the very early accumu-
lation of autoreactive LLPCs in the bone marrow and
spleen of NZB/W mice, our data suggest that a ‘clinically
relevant window of opportunity’ for preventing the accu-
mulation of autoreactive LLPCs would exist only for the
kidney. However, persistent activation and accumulation
of autoreactive LLPCs in the bone marrow may cause re-
lapses in patient with SLE even after long periods of clin-
ical inactivity [6,27]. Therefore other therapies aimed at
targeting LLPCs are needed. LLPCs can be eliminated effi-
ciently by ATG [9], anti-lymphocyte function-associated
antigen 1 (LFA1) plus anti-very late antigen-4 (VLA4)
[15], transmembrane activator and calcium modulator and
cyclophilin ligand interactor-immunoglobulin (TACI-Ig)
[28] and bortezomib [16] also in advanced stage of the dis-
ease. However, therapeutic ablation via these approaches
has two big disadvantages. First, it is not selective for auto-
reactive LLPCs, but also eliminates protective LLPCs in all
cases [9]. Second, in lasting immune reactions and in
autoimmune reactions, LLPC counts quickly recover
within four weeks [15] or two weeks, as shown here for
NZB/W mice and suggested recently for SLE patients
[29]. Moreover, continued elimination of plasma cells can-
not be a preferred therapeutic option since that would
imply long-term immunodeficiency with the complete ab-
sence of humoral immunity and increased infection-
related mortality [30]. Here, we suggest an alternative
approach combining plasma cell ablation therapy with
follow-up treatment to suppress the regeneration of auto-
reactive LLPCs. In the case of bortezomib, this also would
have the additional benefit of reducing unwanted side ef-
fects like neurotoxicity and thrombocytopenia [31]. It
could be argued that also this combination therapy with
agents targeting plasma cells and B cells may promote an
indiscriminate ablation of auotoreactive as well as protect-
ive antibodies with the obvious caveats regarding a higher
risk of infection. Notably, we described that bortezomib
treatment of patients with SLE induced a greater reduc-
tion in pathogenic antibody titers (anti-dsDNA antibodies
58.7% reduction) than protective ones (for example anti-
tetanus antibodies 29.2% reduction) ([29] and Alexander
et al.). Moreover, the administration of cyclophosphamide
for immunosuppression, as used here, is only a proof of
principle. Other more fitting options are available for pa-
tients (that is, depleting B cells with anti-CD20 or target-
ing B cell differentiation into plasma cells and survival
with anti-BAFF). In particular, combined LLPCs targeting
and anti-BAFF therapy (that is, using the approved drug
belimumab) might be a first efficient way to eliminate
LLPCs and on the other hand to interfere with their re-
generation and persistence, with the advantage to contrast
the increased level of BAFF described after B cell depletion
[32,33]. Notably, the use of belimumab instead of a
complete B cell-depletion therapy (for example, usingrituximab) could help to preserve protective memory B
lymphocytes promoting the regeneration only of the pro-
tective LLPC compartment. Indeed, treatment with beli-
mumab is associated with significant reductions in the
numbers of transitional, naive and activated B cells, as well
as CD20 + CD138+ plasma cell precursors (plasmablasts)
[34-36]. Conversely, the number of memory B cells and T
cell is preserved after belimumab therapy indicating that
these cells are independent of BAFF for survival [37]. Con-
sistent with the preservation of memory B cells and T
cells, belimumab treatment does not substantially affect
preexisting anti-pneumococcal or anti-tetanus toxoid anti-
body levels with similar rates of serious and/or severe in-
fections as compared with the placebo-treated group
[34,38-40]. These results, together with the described
greater reduction of autoreactive antibodies after bortezo-
mib in SLE, let us speculate that belimumab combined
with bortezomib treatment might not compromise the im-
mune response to infection dramatically and indiscrimin-
ately. Finally, the combination of LLPC ablation with
immunosuppression would also open options for the se-
lective recovery of protective humoral immunity, for ex-
ample, by vaccination or transfer of autologous, protective
plasma cell precursors. Therefore, our results strongly
suggest that when transferring such plasma cell depletion
strategies to humans, combining plasma cell ablation with
an efficient, preferably selective, ablation of the precursors
of autoreactive LLPCs could be useful.Conclusions
This study explored the generation and maintenance of
autoreactive LLPCs in SLE-prone NZB/W mice and the
kinetic of regeneration of these cells after depletion. We
showed that autoreactive LLPC generation starts very
early in life, long before the onset of disease and that
these cells are constantly generated during disease. Later
in life, LLPCs accumulate in the bone marrow and in-
flamed kidney but not in the spleen. When LLPCs are
depleted by the proteasome inhibitor bortezomib, their
numbers regenerate within two weeks, due to constant B
cell hyperactivity. Persistent depletion of LLPCs was
achieved only by combining a cycle of bortezomib with
maintenance therapy, for example cyclophosphamide,
depleting the precursors of LLPCs or preventing their
differentiation into LLPCs. Our results provide clear evi-
dences that targeting LLPCs in isolation would have lim-
ited efficacy in autoimmune disease. This study enters
into the recent debate concerning which B cell subset
should be targeted in SLE [13,27,32,41], and strongly
suggests that combining plasma cell ablation with an ef-
ficient, preferably selective, ablation of the precursors of
autoreactive LLPCs could represent a new useful strat-
egy in antibody-mediated autoimmune diseases.
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